OncoMatch/Clinical Trials/NCT06349317
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Is NCT06349317 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib for hepatocellular carcinoma.
Treatment: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib — This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular carcinoma with portal vein tumor thrombus.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥1.5×10^9/L; Platelets ≥80×10^9/L; Hemoglobin ≥90g/L
Kidney function
Serum creatinine ≤1.5×ULN, or if >1.5×ULN, creatinine clearance ≥45 mL/min; Urinalysis proteinuria <2+; if baseline proteinuria ≥2+, 24-hour urine protein <1g
Liver function
Total bilirubin ≤3× ULN; ALT and AST ≤5×ULN; Serum albumin ≥30g/L; Child-Pugh Class A
Cardiac function
QTc ≤450ms (males), ≤470ms (females); NYHA class II or above heart failure, LVEF <50%, unstable angina, MI within 1 year, significant arrhythmias excluded
Adequate organ and marrow function, as defined by the following laboratory values: ... Child-Pugh score of Class A; ... QTc > 450ms for males and >470ms for females ... heart failure of NYHA class II or above or echocardiography showing LVEF <50%; unstable angina; myocardial infarction within 1 year before treatment; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06349317 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages